title: Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.
abstract: OBJECTIVE
  This case series highlights the risk of uveitis in patients treated with vemurafenib for unresectable or metastatic cutaneous melanoma.
  
  
  OBJECTIVE
  To assess the occurrence and severity of uveitis as an adverse effect of vemurafenib therapy.
  
  
  METHODS
  In this observational small case series, data were collected successively from May 1, 2012, through February 31, 2013, from patients with clinical signs of ocular inflammation treated with vemurafenib at the Department of Ophthalmology, Cochin-Hôtel-Dieu Hospital.
  
  
  METHODS
  Patients' demographics, vemurafenib dosages, and the intervals between the onset of treatment and the first ocular symptoms were recorded. The characteristics of ocular inflammatory manifestations were analyzed. The effect of the discontinuation of vemurafenib therapy on ocular manifestations was assessed, as well as the effect of rechallenging when vemurafenib was reintroduced.
  
  
  RESULTS
  Seven patients (mean [SD] age, 74.7 [4.0] years) had uveitis. The vemurafenib dose was 960 mg twice per day in 6 patients and a half dose in 1 patient. The mean (SD) time until the appearance of ocular signs was 5.6 (2.3) months (range, 19 days to 7 months), and inflammation ranged from mild or low-grade anterior uveitis to severe explosive panuveitis complicated by retinal detachment. Signs of ocular inflammation were always bilateral. Optical coherence tomography revealed a macular edema in only 1 of the 7 patients. Clinical improvement occurred when vemurafenib therapy was stopped in 5 of 7 patients. The rechallenge at treatment reintroduction was positive in 2 of 7 patients.
  
  
  CONCLUSIONS
  This small case series highlights that uveitis can be a noteworthy adverse effect of vemurafenib therapy in patients with metastatic cutaneous melanoma. However, these cases of uveitis were usually restricted to the anterior segment and manageable with local corticosteroid therapy, which justified the continuation of vemurafenib therapy because the benefits regarding the patients' survival were greater than the risk to their vision.
authors.affiliation: Department of Ophthalmology, Cochin-Hôtel-Dieu Hospital, Paris, France2Faculté de Médecine, Université Paris Descartes, Paris, France.
authors.forename: Mikael
authors.initials: M
authors.lastname: Guedj
authors.affiliation: Department of Ophthalmology, Cochin-Hôtel-Dieu Hospital, Paris, France2Faculté de Médecine, Université Paris Descartes, Paris, France.
authors.forename: Astrid
authors.initials: A
authors.lastname: Quéant
authors.affiliation: Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France.
authors.forename: Elisa
authors.initials: E
authors.lastname: Funck-Brentano
authors.affiliation: Faculté de Médecine, Université Paris Descartes, Paris, France4Department of Dermatology, Cochin Hospital, Paris, France.
authors.forename: Nora
authors.initials: N
authors.lastname: Kramkimel
authors.affiliation: Department of Ophthalmology, Cochin-Hôtel-Dieu Hospital, Paris, France.
authors.forename: Judith
authors.initials: J
authors.lastname: Lellouch
authors.affiliation: Department of Ophthalmology, Cochin-Hôtel-Dieu Hospital, Paris, France2Faculté de Médecine, Université Paris Descartes, Paris, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Monnet
authors.affiliation: Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Longvert
authors.affiliation: Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France.
authors.forename: Amelie
authors.initials: A
authors.lastname: Gantzer
authors.affiliation: Department of Ophthalmology, Cochin-Hôtel-Dieu Hospital, Paris, France2Faculté de Médecine, Université Paris Descartes, Paris, France.
authors.forename: Antoine P
authors.initials: AP
authors.lastname: Brézin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D015423:Scleritis / Q000139:chemically induced; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects*; D013997:Time Factors; D041623:Tomography, Optical Coherence; D014605:Uveitis / Q000139:chemically induced* / Q000175:diagnosis; D000077484:Vemurafenib; D048490:raf Kinases / Q000037:antagonists & inhibitors*
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; D048490:raf Kinases